Abstract
The immunosuppressive oligonucleotide cyclosporine A (CsA) is extensively used in organ transplantation and autoimmune disorders. CsA as well as FK506 is a typical inhibitor of calcineurin, a serine/threonine phosphatase. Calcineurin is a potent regulator for fiber-type conversion, regeneration, and muscle hypertrophy of slow-twitch fibers. Many researchers including our group have used CsA delivered orally, intraperitoneally, or subcutaneously to modulate calcineurin activity. In this review, we have systematically and descriptively dealt with the role of CsA in regulating muscle adaptations in mature mammals. Pharmacological inhibition by CsA delays the muscle regenerating process. Some limitations are observed, because treatment with CsA in vivo blocks all of the calcineurin subtypes. A strategy for controlling the amount of calcineurin may be effective for the treatment of muscular disorders such as Duchenne muscular dystrophy (DMD), Ullrich congenital muscular dystrophy (UCMD), and limb-girdle muscular dystrophy (LGMD). Lowdose and short-term (2-6 weeks) CsA treatment would help to elucidate the functional role of calcineurin in skeletal muscle in vivo.
Keywords: Cyclosporine A, calcineurin, regeneration, hypertrophy, fiber type, muscular dystrophy, skeletal muscle, cyclophilin D, autoimmune disorders, calmodulin
Current Enzyme Inhibition
Title: Current Application of Cyclosporine A to Investigate Skeletal Muscle Adaptation
Volume: 7 Issue: 3
Author(s): Kunihiro Sakuma and Akihiko Yamaguchi
Affiliation:
Keywords: Cyclosporine A, calcineurin, regeneration, hypertrophy, fiber type, muscular dystrophy, skeletal muscle, cyclophilin D, autoimmune disorders, calmodulin
Abstract: The immunosuppressive oligonucleotide cyclosporine A (CsA) is extensively used in organ transplantation and autoimmune disorders. CsA as well as FK506 is a typical inhibitor of calcineurin, a serine/threonine phosphatase. Calcineurin is a potent regulator for fiber-type conversion, regeneration, and muscle hypertrophy of slow-twitch fibers. Many researchers including our group have used CsA delivered orally, intraperitoneally, or subcutaneously to modulate calcineurin activity. In this review, we have systematically and descriptively dealt with the role of CsA in regulating muscle adaptations in mature mammals. Pharmacological inhibition by CsA delays the muscle regenerating process. Some limitations are observed, because treatment with CsA in vivo blocks all of the calcineurin subtypes. A strategy for controlling the amount of calcineurin may be effective for the treatment of muscular disorders such as Duchenne muscular dystrophy (DMD), Ullrich congenital muscular dystrophy (UCMD), and limb-girdle muscular dystrophy (LGMD). Lowdose and short-term (2-6 weeks) CsA treatment would help to elucidate the functional role of calcineurin in skeletal muscle in vivo.
Export Options
About this article
Cite this article as:
Sakuma Kunihiro and Yamaguchi Akihiko, Current Application of Cyclosporine A to Investigate Skeletal Muscle Adaptation, Current Enzyme Inhibition 2011; 7 (3) . https://dx.doi.org/10.2174/157340811798807632
DOI https://dx.doi.org/10.2174/157340811798807632 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Systematic Review on Levosimendan in Paediatric Patients
Current Vascular Pharmacology Lipids and Non-Cardiac Vascular Disease: A Lecture Overview
Current Vascular Pharmacology MicroRNAs and Ischemic Heart Disease: Towards a Better Comprehension of Pathogenesis, New Diagnostic Tools and New Therapeutic Targets
Recent Patents on Cardiovascular Drug Discovery Perspectives on New Synthetic Curcumin Analogs and their Potential Anticancer Properties
Current Pharmaceutical Design Novel Systemic Cardiovascular Disease Biomarkers
Current Molecular Medicine Mitochondrial Oxidative Stress and Heart Failure ∼Novel Pathophysiological Insight and Treatment Strategies∼
Current Cardiology Reviews Association Between Polycystic Ovary Syndrome and Metabolic Syndrome
Current Medicinal Chemistry Natural Products as Anti-glycation Agents: Possible Therapeutic Potential for Diabetic Complications
Current Diabetes Reviews A Single Pill to Treat Postmenopausal Hypertension? Not Yet
Current Topics in Medicinal Chemistry Prophylactic Vaccine Approach for Colon and Pancreatic Cancers: Present and Future
Current Medicinal Chemistry Vitamin E and All-Cause Mortality: A Meta-Analysis
Current Aging Science Chemical Constituents and Biological Significance of the Genus Ilex (Aquifoliaceae)
The Natural Products Journal Psychological Stress in Pathogenesis of Essential Hypertension
Current Hypertension Reviews Experimental Strategies in Autoimmunity: Antagonists of Cytokines and their Receptors, Nanocarriers, Inhibitors of Immunoproteasome, Leukocyte Migration and Protein Kinases
Current Pharmaceutical Design Therapeutic Challenges in Neuroendocrine Tumors
Anti-Cancer Agents in Medicinal Chemistry Integrin Signaling Networks in the Pathobiology of Vascular Smooth Muscle Cells
Vascular Disease Prevention (Discontinued) Targeting Toll-like Receptors in Autoimmunity
Current Drug Targets Impact of Ultrasound Contrast Agents in Echocardiographic Assessment of Ischemic Heart Disease
Recent Patents on Cardiovascular Drug Discovery The Potential Role of Antioxidants in Metabolic Syndrome
Current Pharmaceutical Design The ATP-Binding Cassette Transporter Subfamily A Member 1 (ABC-A1) and Type 2 Diabetes: An Association Beyond HDL Cholesterol
Current Diabetes Reviews